On October 9, 2015 Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, reported that it will present new data on its myRisk Hereditary Cancer molecular diagnostic test at the 18th Annual Meeting of the Collaborative Group of the Americas – Inherited Colorectal Cancer (CGA-ICC) being held Oct. 11 to 12, 2015 in Baltimore, Md (Press release, Myriad Genetics, OCT 9, 2015, View Source [SID:1234507681]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Myriad is committed to improving the care of patients and families with inherited colorectal cancer syndromes," said Johnathan Lancaster, M.D., Ph.D., chief medical officer, Myriad Genetic Laboratories. "These syndromes are under-diagnosed and our new data using the myRisk Hereditary Cancer gene panel test highlight how next generation sequencing technology can identify more patients at elevated risk of hereditary colon cancer. This information empowers patients and their physicians to take steps that may reduce the risk of a cancer developing. Our recent studies focus on expanding our understanding of the gene mutations associated with colorectal cancer syndromes, and we believe that these data provide further evidence that testing guidelines need to be revised to ensure that patients continue to have access to advances in sequencing technology that may be life-saving."
A list of the Myriad presentations at CGA-ICC (#CGA2015) follows:
Podium Presentations
Title: Pan-cancer gene panel results for patients with > 5 adenomas.
Date: Monday, Oct. 12, 2015, 9:00 a.m. ET.
Title: Ohio Colorectal Cancer Prevention Initiative: Germline mutation spectrum in 250 colorectal cancer patients diagnosed under age 50.
Date: Monday, Oct. 12, 2015: 9:10 a.m. ET.
Poster Presentation
Title: Clinical Presentations of Patients and Families Identified with Pathogenic Variants in CDH1.
Date: Monday, Oct. 12, 2015: 7:30 a.m. ET.
For more information about the meeting, please visit the CGA website at: View Source
About Myriad myRisk Hereditary Cancer Testing
The Myriad myRisk Hereditary Cancer test uses next-generation sequencing technology to evaluate 25 clinically significant genes associated with eight hereditary cancer sites including: breast, colon, ovarian, endometrial, pancreatic, prostate and gastric cancers and melanoma. For more information visit: View Source